138 related articles for article (PubMed ID: 3172354)
21. A transient increase in serum procollagen 1 carboxyterminal peptide following effective treatment in prostate cancer patients with bone metastases.
Nakashima J; Sumitomo M; Miyajima A; Jitsukawa S; Murai M
Urol Int; 1997; 58(4):236-8. PubMed ID: 9253125
[TBL] [Abstract][Full Text] [Related]
22. Hypocalcemia and parathyroid function in metastatic prostate cancer.
Tandon PK; Rizvi AA
Endocr Pract; 2005; 11(4):254-8. PubMed ID: 16006299
[TBL] [Abstract][Full Text] [Related]
23. Pamidronate, hypocalcemia, and calcium and vitamin D supplementation.
Altundag O; Altundag K
J Clin Oncol; 2004 May; 22(10):2035; author reply 2035. PubMed ID: 15143101
[No Abstract] [Full Text] [Related]
24. Severe hypocalcaemia associated with extensive osteoblastic metastases in a patient with prostate cancer.
Fokkema MI; de Heide LJ; van Schelven WD; Hamdy NA
Neth J Med; 2005 Jan; 63(1):34-7. PubMed ID: 15719851
[TBL] [Abstract][Full Text] [Related]
25. Gallium nitrate in prostatic cancer: evaluation of antitumor activity and effects on bone turnover.
Scher HI; Curley T; Geller N; Dershaw D; Chan E; Nisselbaum J; Alcock N; Hollander P; Yagoda A
Cancer Treat Rep; 1987 Oct; 71(10):887-93. PubMed ID: 3308078
[TBL] [Abstract][Full Text] [Related]
26. High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.
Kinoshita Y; Arai M; Ito N; Takashi Y; Makita N; Nangaku M; Shinoda Y; Fukumoto S
Endocr J; 2016 May; 63(5):479-84. PubMed ID: 26860123
[TBL] [Abstract][Full Text] [Related]
27. [Tumoral hypocalcemia].
Riancho JA; Arjona R; Echevarría S; Amado JA; González Macías J
Rev Clin Esp; 1989 Mar; 184(4):187-9. PubMed ID: 2740546
[TBL] [Abstract][Full Text] [Related]
28. [Does diethylstilbestrol still have a role in the treatment of bone metastasis in prostatic cancer? Apropos of 2 cases with unusually long survival time].
Brantus JF; Bouvier M
Rev Rhum Ed Fr; 1993 Nov; 60(11):844-6. PubMed ID: 8054936
[No Abstract] [Full Text] [Related]
29. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
Body JJ; Bone HG; de Boer RH; Stopeck A; Van Poznak C; Damião R; Fizazi K; Henry DH; Ibrahim T; Lipton A; Saad F; Shore N; Takano T; Shaywitz AJ; Wang H; Bracco OL; Braun A; Kostenuik PJ
Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
[TBL] [Abstract][Full Text] [Related]
30. Severe hypocalcemia due to osteoblastic metastasis of prostate cancer.
Diéguez Felechosa M; Noval Menéndez J; Manjón Miguelez L
Med Clin (Barc); 2017 Mar; 148(6):287-288. PubMed ID: 28118964
[No Abstract] [Full Text] [Related]
31. Hypocalcemia with bony metastases in prostate cancer.
Pusulari BB; Akbar RA; Butt M; ul Haq SM
J Ayub Med Coll Abbottabad; 2008; 20(1):138-9. PubMed ID: 19024209
[TBL] [Abstract][Full Text] [Related]
32. Hypocalcaemia following denosumab in prostate cancer: A clinical review.
Lau LH; Cliff ERS; Wong V; Wong H; Torkamani N; Eer A; Weickhardt A; Grossmann M
Clin Endocrinol (Oxf); 2020 Jun; 92(6):495-502. PubMed ID: 32017154
[TBL] [Abstract][Full Text] [Related]
33. [Metastatic prostate cancer complicated with chronic disseminated intravascular coagulopathy causing acute renal failure, mimicking thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: pathomechanism, differential diagnosis and therapy related to a case].
Deme D; Ragán M; Kalmár K; Kovács L; Varga E; Varga T; Rakonczai E
Magy Onkol; 2010 Dec; 54(4):351-7. PubMed ID: 21163766
[TBL] [Abstract][Full Text] [Related]
34. Osteomalacia associated with prostatic cancer and osteoblastic metastases.
Kabadi UM
Urology; 1983 Jan; 21(1):65-7. PubMed ID: 6687413
[TBL] [Abstract][Full Text] [Related]
35. Prostate-Specific Antigen Flare Phenomenon During
De Vincentis G; Follacchio GA; Frantellizzi V; Liberatore M; Monteleone F; Cortesi E
Clin Genitourin Cancer; 2016 Oct; 14(5):e529-e533. PubMed ID: 27212044
[No Abstract] [Full Text] [Related]
36. [Clinical analysis and treatment of carcinoma of the prostate with bone metastasis].
Kawai T; Washizuka M; Yamauchi T; Ishibashi Y; Sumi S; Kokuho M
Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 2):1704-9. PubMed ID: 3592710
[TBL] [Abstract][Full Text] [Related]
37. Isolated calcaneal metastasis from prostate cancer.
Agrawal S; Irvine A; Money-Kyrle J; Ellis BW
Ann R Coll Surg Engl; 2008 Apr; 90(3):W7-9. PubMed ID: 18430327
[TBL] [Abstract][Full Text] [Related]
38. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline.
Berruti A; Dogliotti L; Bitossi R; Fasolis G; Gorzegno G; Bellina M; Torta M; Porpiglia F; Fontana D; Angeli A
J Urol; 2000 Oct; 164(4):1248-53. PubMed ID: 10992374
[TBL] [Abstract][Full Text] [Related]
39. Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism.
Mishra A; Wong L; Jonklaas J
Endocrine; 2001 Mar; 14(2):159-64. PubMed ID: 11394632
[TBL] [Abstract][Full Text] [Related]
40. Hypocalcemia associated with metastatic bone disease. A retrospective study.
Raskin P; McClain CJ; Medsger TA
Arch Intern Med; 1973 Oct; 132(4):539-43. PubMed ID: 4742409
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
